Selective ERAP2 Inhibitors for Antigen Presentation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for efficient and selective inhibitors of endoplasmic reticulum aminopeptidases (ERAP), particularly ERAP2, to modulate antigen presentation and immune responses, which are implicated in disorders such as proliferative, autoimmune, and autoinflammatory diseases.
Innovation Solution
Development of novel compounds of formula (I) that inhibit ERAP enzymes, specifically ERAP2, by targeting specific functional groups and structures, including phenyl, naphthalenyl, indolyl, and benzodioxolyl moieties, with varying substituents, to modulate antigenic peptide presentation and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ERAP enzymes are active to process antigenic peptides, then immune response is enhanced, but autoimmune and autoinflammatory diseases are promoted
Solution Approach 1:
The patent applies parameter changes by developing compounds that selectively modulate ERAP2 enzymatic activity. The compounds of formula (I) are designed to alter the kinetic parameters of ERAP2, reducing its ability to process certain antigenic peptides while maintaining overall immune function. This selective parameter modification resolves the contradiction by tuning enzyme activity to a therapeutic window that prevents autoimmune pathology without compromising immune surveillance.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries between the ERAP2 enzyme and antigenic peptides. These compounds bind to ERAP2 and act as mediators that prevent the enzyme from processing self-peptides into pathogenic epitopes, while allowing continued processing of foreign antigenic peptides. This intermediary mechanism selectively blocks harmful interactions without abolishing beneficial immune responses.
2Object-affected harmful factors
If ERAP inhibitors are developed to treat autoimmune diseases, then autoimmune pathology is reduced, but immune response to infections and tumors may be compromised
Solution Approach 1:
The patent applies local quality by designing ERAP2 inhibitors with selective binding characteristics that target specific substrate peptides associated with autoimmune pathology. The compounds of formula (I) exhibit differential inhibition patterns, strongly blocking processing of self-peptides that generate pathogenic epitopes while having minimal impact on processing of foreign antigenic peptides from pathogens and tumors. This local selectivity resolves the contradiction by applying inhibition only where harmful.
Solution Approach 2:
The patent employs partial action by developing inhibitors that achieve sufficient blockade of pathogenic peptide processing without completely abolishing ERAP2 activity. The compounds are designed to reduce enzyme activity to a therapeutic threshold that prevents autoimmune epitope generation while preserving enough residual activity to maintain immune surveillance against infections and tumors. This partial inhibition strategy balances therapeutic benefit with immune competence.
Data Source
AI summary
The present disclosure relates to novel compounds of formula (I) which are useful as inhibitors of endoplasmic reticulum aminopeptidases (ERAP), in particular as inhibitors of ERAP2. The disclosure also relates to the therapeutic use of these compounds, in particular the use of these compounds in the treatment or prophylaxis of proliferative disorders, autoinflammatory disorders and autoimmune disorders.